IMMUPHARMA PLC — Regulatory Filings 2017

Mar 20, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9558Z

Immupharma PLC

20 March 2017

	20 MARCH 2017

ImmuPharma PLC

("ImmuPharma" or the "Company")

TR1 NOTIFICATION OF MAJOR INTEREST

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has today received a TR-1 by Aviva plc ("Aviva"). Aviva's holding in ImmuPharma is now confirmed at a total of 10,280,516 Ordinary Shares which equates to a current position in the Company of 7.76% of ImmuPharma's total voting rights figure of 132,522,985 Ordinary Shares.

Full disclosure of the TR1 is shown below:

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii			Immupharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached				√
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PLACING			√
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s) (if different from 3.):iv		Registered Holder: Chase (GA Group) Nominees Limited   : 7,361,243* HSBC Global Custody Nominee (UK) Limited : 1,606,013* State Street Nominees Limited  : 200,974* *denotes direct interest   Chase (GA Group) Nominees Limited  :  409,378 Chase Nominees Limited    : 248,294 Vidacos Nominees Limited       : 436,614
5. Date of the transaction and date on which the threshold is crossed or reached: v		16 March 2017
6. Date on which issuer notified:		17 March 2017
7. Threshold(s) that is/are crossed or reached: vi, vii		7% to 6% Change at Direct Interest Level (Box 8A)

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights		% of  voting rights x
Direct	Direct xi	Indirect xii	Direct		Indirect
Ordinary Shares GB0033711010	11,169,942		11,169,942		10,262,516	9,168,230	1,094,286	6.92%		0.83%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date xiii		Exercise/ Conversion Period xiv		Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights
RIGHT TO RECALL LOANED SHARES		N/A		N/A		18,000* *DIRECT INTEREST			0.01%

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx

Total (A+B+C)
Number of voting rights	Percentage of voting rights
10,280,516	7.76%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based the revised total number of voting rights of 132,522,985 as per the recent £4.1 Million Fund Raise via Accelerated Bookbuild announcement of 10 March 2017.
14. Contact name:	Neil Whittaker, Aviva plc
15. Contact telephone number:	01603 684420

-Ends-

For further information please contact:

ImmuPharma plc (www.immupharma.org)	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma	+ 44 (0) 7721 413496
Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance Rob Rees, Corporate Broking	+44 (0)20 3861 6625

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLFBLFLDXFXBBV